(Taken from the application) The CURE: Digestive Diseases Research Center is composed of a cohesive group of physicians and basic scientists with strong independent grant-supported research programs in the biology of the gut, with special emphasis upon regulation of mucosal cell function and gut neuroscience. CURE first received NIDDK funding in 1974 as a center to study peptic ulcer disease and became a Digestive Disease Core Center in 1989. The research emphasis of the center is acquisition of new knowledge about cellular and physiological processes that control gut function and translation of this knowledge into development of therapy for patients with gastrointestinal diseases. CURE initially established its reputation for work in clinical peptic ulcer disease, physiological regulation of acid secretion, and parietal cell mechanisms for secreting acid. Demonstration that Helicobacter pylori is an essential factor in pathogenesis of ordinary peptic ulcer disease brought new aspects of mucosal cell biology into the forefront of research at CURE. The interests and activities of center members have evolved along with science in this area and now include several facets of gastrointestinal regulatory physiology and cell biology. CURE's new name reflects more appropriately the broad interests of its members, including gastroduodenal mucosal physiology and disease; intestinal transport, intestinal inflammation, nutrition, and pancreatic secretion; neurophysiology and neuroenteric disease; and hormones, receptors, and signal transduction. The five Biomedical Research Cores outlined in this proposal provide ready access to technology and to clinical and biological materials that are essential to the programs of center members. These cores provide custom antibody production, sophisticated peptide chemistry techniques, access to modem cellular imaging to study membrane proteins and their functions, animal models for studying physiology and pathophysiology, and access to a broad range of techniques and patients for clinical studies. The Administrative Core provides a wide range of administrative support for members and for center activities including a dynamic enrichment program. The Pilot and Feasibility Program has provided a successful mechanism for aiding development of new research programs by young investigators, and recipients usually have obtained independent funding. The center provides an optimal environment for cooperation and collaboration among its investigators, who have had a major impact on mucosal biology and on peptic ulcer disease over the past two decades and promise to have an even larger impact upon expanded research areas with continued support from the center.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
2P30DK041301-11
Application #
2901654
Study Section
Special Emphasis Panel (ZDK1-GRB-7 (M1))
Program Officer
Podskalny, Judith M,
Project Start
1990-01-15
Project End
2004-11-30
Budget Start
2000-06-01
Budget End
2000-11-30
Support Year
11
Fiscal Year
2000
Total Cost
$880,000
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Bonfiglio, Ferdinando; Zheng, Tenghao; Garcia-Etxebarria, Koldo et al. (2018) Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome. Gastroenterology 155:168-179
Hoffman, Jill M; Sideri, Aristea; Ruiz, Jonathan J et al. (2018) Mesenteric Adipose-derived Stromal Cells From Crohn's Disease Patients Induce Protective Effects in Colonic Epithelial Cells and Mice With Colitis. Cell Mol Gastroenterol Hepatol 6:1-16
Kageyama, Shoichi; Nakamura, Kojiro; Fujii, Takehiro et al. (2018) Recombinant relaxin protects liver transplants from ischemia damage by hepatocyte glucocorticoid receptor: From bench-to-bedside. Hepatology 68:258-273
Wen, Yi; Scott, David R; Vagin, Olga et al. (2018) Measurement of Internal pH in Helicobacter pylori by Using Green Fluorescent Protein Fluorimetry. J Bacteriol 200:
Koon, Hon Wai; Wang, Jiani; Mussatto, Caroline C et al. (2018) Fidaxomicin and OP-1118 Inhibit Clostridium difficile Toxin A- and B-Mediated Inflammatory Responses via Inhibition of NF-?B Activity. Antimicrob Agents Chemother 62:
Wang, Jiani; Ghali, Sally; Xu, Chunlan et al. (2018) Ceragenin CSA13 Reduces Clostridium difficile Infection in Mice by Modulating the Intestinal Microbiome and Metabolites. Gastroenterology 154:1737-1750
Manatsathit, Wuttiporn; Khrucharoen, Usah; Jensen, Dennis M et al. (2018) Laparotomy and intraoperative enteroscopy for obscure gastrointestinal bleeding before and after the era of video capsule endoscopy and deep enteroscopy: A tertiary center experience. Am J Surg 215:603-609
Rankin, Carl Robert; Theodorou, Evangelos; Man Law, Ivy Ka et al. (2018) Identification of novel mRNAs and lncRNAs associated with mouse experimental colitis and human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 315:G722-G733
Park, S H; Naliboff, B D; Shih, W et al. (2018) Resilience is decreased in irritable bowel syndrome and associated with symptoms and cortisol response. Neurogastroenterol Motil 30:
Dong, Tien; Pisegna, Joseph (2018) Passing the ""Acid Test"": Do Proton Pump Inhibitors Affect the Composition of the Microbiome? Dig Dis Sci :

Showing the most recent 10 out of 1097 publications